Monkeypox is a self-limiting disease with symptoms lasting between two and four weeks. However, hospitalization, in some cases, suggests the need for effective therapy. A recent small-scale preclinical study has found Tecovirimat to be effective against smallpox and monkeypox . Tecovirimat works by inhibiting p37, a protein involved in the release, dissemination, and virulence of the enveloped virus.
The study revealed that the oral tecovirimat (consumed every 8 or 12 hours, for 14 days or more) was generally well tolerated by adults (n = 25) with systemic symptoms and lesions without the need for discontinuation. Lesions resolved completely in 40% of patients on day 7 of therapy and 92% by day 21. Common adverse events on day 7 included fatigue, headache, nausea, itching, and diarrhea . However, researchers recommend caution when deciding on tecovirimat use as the study did not include…
